3//SEC Filing
Frazier Life Sciences IX, L.P. 3
Accession 0001209191-20-054997
CIK 0001819790other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 8:27 PM ET
Size
12.3 KB
Accession
0001209191-20-054997
Insider Transaction Report
Form 3
FHMLS IX, L.L.C.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (1,390,376 underlying)Series C Preferred Stock
→ Common Stock (214,281 underlying)
Topper James N
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (1,390,376 underlying)Series C Preferred Stock
→ Common Stock (214,281 underlying)
FHMLS IX, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (1,390,376 underlying)Series C Preferred Stock
→ Common Stock (214,281 underlying)
Frazier Life Sciences IX, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (1,390,376 underlying)Series C Preferred Stock
→ Common Stock (214,281 underlying)
Heron Patrick J
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (1,390,376 underlying)Series C Preferred Stock
→ Common Stock (214,281 underlying)
Footnotes (3)
- [F1]The Series B Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
- [F2]The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein
- [F3]The Series C Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series C Preferred Stock has no expiration date.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001720320
Filing Metadata
- Form type
- 3
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 8:27 PM ET
- Size
- 12.3 KB